D. Boral Capital Initiates Coverage of Estrella Immunopharma with Buy Rating and $16 Price Target

US Stocks News: On February 18, D. Boral Capital initiated coverage of Estrella with a Buy rating and set an initial target price of $16.00.

Estrella Immunopharma, Inc. was incorporated in Delaware on March 30, 2022. The company is a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS T-cell therapies, with the capability to address treatment challenges for patients with hematologic cancers and solid tumors. The company’s mission is to transform the lives of cancer patients by harnessing the evolutionary power of the human immune system. To fulfill this mission, its lead candidate, EB103, leverages Eureka’s ARTEMIS technology to target CD19, a protein expressed on the surface of nearly all B-cell leukemias and lymphomas. The company is also developing EB104, which likewise utilizes Eureka’s ARTEMIS technology to target not only CD19 but also CD22, a protein expressed on the surface of most B-cell malignancies, similar to CD19.

Estrella released its first-quarter 2025 earnings report on November 14, reporting a net loss of $3.3767 million and basic earnings per share of -$0.09 for the period ended September 30, 2024.

Report Download:Estrella Immunopharma: Introducing the Next Generation of CAR-T Therapies

Data Source: iFinD by Tonghuashun